About Kelch-like protein 42
Kelch-like protein 42 (KLHL42) is a protein
from Homo sapiens identified by UniProt accession
Q9P2K6, 505 residues long.
MolForge cross-references it against 0 known binders and
56 disease associations.
Target properties
| Protein name | Kelch-like protein 42 |
| UniProt accession | Q9P2K6 |
| Gene | KLHL42 |
| Organism | Homo sapiens |
| Length | 505 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (56)
Diseases linked to this target (Open Targets).
- type 2 diabetes mellitus · score 0.45
- diabetes mellitus · score 0.42
- pulse pressure measurement · score 0.38
- gut microbiome measurement · score 0.36
- osteoarthritis, hip · score 0.36
- glucose measurement · score 0.35
- Drugs used in diabetes use measurement · score 0.35
- vital capacity · score 0.33
- osteoarthritis · score 0.32
- PHF-tau measurement · score 0.32
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9P2K6-F1 | alphafold | PREDICTED | 85.42 | — |
Amino-acid sequence (505 residues)
MSAEEMVQIR LEDRCYPVSK RKLIEQSDYF RALYRSGMRE ALSQEAGGPE VQQLRGLSAP GLRLVLDFIN AGGAREGWLL GPRGEKGGGV DEDEEMDEVS LLSELVEAAS FLQVTSLLQL LLSQVRLNNC LEMYRLAQVY GLPDLQEACL RFMVVHFHEV LCKPQFHLLG SPPQAPGDVS LKQRLREARM TGTPVLVALG DFLGGPLAPH PYQGEPPSML RYEEMTERWF PLANNLPPDL VNVRGYGSAI LDNYLFIVGG YRITSQEISA AHSYNPSTNE WLQVASMNQK RSNFKLVAVN SKLYAIGGQA VSNVECYNPE QDAWNFVAPL PNPLAEFSAC ECKGKIYVIG GYTTRDRNMN ILQYCPSSDM WTLFETCDVH IRKQQMVSVE ETIYIVGGCL HELGPNRRSS QSEDMLTVQS YNTVTRQWLY LKENTSKSGL NLTCALHNDG IYIMSRDVTL STSLEHRVFL KYNIFSDSWE AFRRFPAFGH NLLVSSLYLP NKAET
Explore Kelch-like protein 42 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets